Capital Performance Advisors’s XBiotech XBIT Stock Holding History

Capital Performance Advisors’s Portfolio XBIT Stock Details XBIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1	Closed	-$8	–	2733
2024 Q3	$8	Buy	+1	New	+$7	﹤0.01%	2886

Other funds holding XBIT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Capital Performance Advisors's XBIT Position: Q4 2024 in Review

Capital Performance Advisors sold out of XBiotech (XBIT) in Q4 2024, closing a stake of 1 share — an estimated $8 sold.

Capital Performance Advisors first reported a position in XBIT in Q3 2024 and held it in 1 quarter. The position peaked at $8 in Q3 2024. 53 funds tracked by Wall St. Rank hold XBIT as of Q4 2024.

Capital Performance Advisors reported no remaining XBiotech position as of Q4 2024 after selling out during the quarter.
Capital Performance Advisors sold 1 XBiotech share in Q4 2024, an estimated $8.
Capital Performance Advisors first reported a position in XBiotech in Q3 2024 and held it in 1 quarter.
Capital Performance Advisors's XBiotech position peaked at $8 in Q3 2024.
53 funds tracked by Wall St. Rank held XBiotech as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.